423 related articles for article (PubMed ID: 26413868)
1. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
[TBL] [Abstract][Full Text] [Related]
2. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
[TBL] [Abstract][Full Text] [Related]
3. Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART
Tuyishime M; Dashti A; Faircloth K; Jha S; Nordstrom JL; Haynes BF; Silvestri G; Chahroudi A; Margolis DM; Ferrari G
Front Immunol; 2021; 12():710273. PubMed ID: 34484212
[TBL] [Abstract][Full Text] [Related]
4. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
[TBL] [Abstract][Full Text] [Related]
5. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
Euler Z; Alter G
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):13-24. PubMed ID: 25385703
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.
Lee WS; Richard J; Lichtfuss M; Smith AB; Park J; Courter JR; Melillo BN; Sodroski JG; Kaufmann DE; Finzi A; Parsons MS; Kent SJ
J Virol; 2016 Feb; 90(4):2021-30. PubMed ID: 26656700
[TBL] [Abstract][Full Text] [Related]
7. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.
Sung JA; Lam S; Garrido C; Archin N; Rooney CM; Bollard CM; Margolis DM
J Infect Dis; 2015 Jul; 212(2):258-63. PubMed ID: 25589335
[TBL] [Abstract][Full Text] [Related]
8. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
[TBL] [Abstract][Full Text] [Related]
9. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
[TBL] [Abstract][Full Text] [Related]
10. Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.
Curriu M; Fausther-Bovendo H; Pernas M; Massanella M; Carrillo J; Cabrera C; López-Galíndez C; Clotet B; Debré P; Vieillard V; Blanco J
PLoS One; 2012; 7(2):e30330. PubMed ID: 22312424
[TBL] [Abstract][Full Text] [Related]
11. Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells.
Heinkelein M; Sopper S; Jassoy C
J Virol; 1995 Nov; 69(11):6925-31. PubMed ID: 7474110
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals.
Ahmad A; Morisset R; Thomas R; Menezes J
J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):428-37. PubMed ID: 7908983
[TBL] [Abstract][Full Text] [Related]
13. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo.
Tanneau F; McChesney M; Lopez O; Sansonetti P; Montagnier L; Rivière Y
J Infect Dis; 1990 Oct; 162(4):837-43. PubMed ID: 1698205
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
[TBL] [Abstract][Full Text] [Related]
15. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure.
Kent SJ; Greenberg PD; Hoffman MC; Akridge RE; McElrath MJ
J Immunol; 1997 Jan; 158(2):807-15. PubMed ID: 8992998
[TBL] [Abstract][Full Text] [Related]
17. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
18. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
19. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
20. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
